Plain-English translation of NCT06802315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to prepare patients for stem cell transplants using a combination of chemotherapy drugs (fludarabine and busulfan), a newer type of radiation called intensity modulated total marrow irradiation, and post-transplant cyclophosphamide. The goal is to help patients with hard-to-treat blood cancers — like acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome — have better outcomes after receiving a transplant from a matched or partially matched donor.
Standard transplant preparations don't work well enough for patients with high-risk blood cancers. Researchers are testing whether this new combination of treatments can better eliminate cancer cells while making the transplant safer and more likely to succeed.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy infusions for four days, then radiation therapy for three days, followed by an infusion of stem cells on day zero. You would also receive additional medications to prevent rejection and infection. You would have follow-up appointments at your transplant center at 30 days, 60 days, 90 days, 6 months, 1 year, and 2 years after transplant to check how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States